Scholefield Melissa, Church Stephanie J, Xu Jingshu, Robinson Andrew C, Gardiner Natalie J, Roncaroli Federico, Hooper Nigel M, Unwin Richard D, Cooper Garth J S
Centre for Advanced Discovery & Experimental Therapeutics, Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester M19 9NT, UK.
School of Biological Sciences, Faculty of Science, University of Auckland, Private Bag 92 019, Auckland 1142, New Zealand.
Metabolites. 2020 Oct 29;10(11):438. doi: 10.3390/metabo10110438.
The use of post-mortem human tissue is indispensable in studies investigating alterations in metabolite levels in neurodegenerative conditions such as Alzheimer's disease (AD). However, variability between samples may have unknown effects on metabolite concentrations. The aim of this study was to characterize the impact of such variables. Cingulate gyrus was obtained from AD cases and controls, from three brain banks. Gas chromatography-mass spectrometry (GC-MS) was used to measure and compare the levels of 66 identifiable metabolites in these tissues to determine effects of tissue-collection variables. The effect of PMD was further investigated by analysis of rat brain cortex and cerebellum collected following post-mortem delays (PMDs) of zero to 72 h. Metabolite levels between cases and controls were not replicable across cohorts with variable age- and gender-matching, PMD, and control Braak staging. Analysis of rat tissues found significant effects of PMD on 31 of 63 identified metabolites over periods up to 72 h. PMD must be kept under 24 h for metabolomics analyses on brain tissues to yield replicable results. Tissues should also be well age- and gender-matched, and Braak stage in controls should be kept to a minimum in order to minimize the impact of these variables in influencing metabolite variability.
在研究诸如阿尔茨海默病(AD)等神经退行性疾病中代谢物水平变化时,使用死后人体组织是必不可少的。然而,样本之间的变异性可能会对代谢物浓度产生未知影响。本研究的目的是表征此类变量的影响。扣带回取自三个脑库的AD病例和对照。采用气相色谱-质谱联用(GC-MS)技术测量并比较这些组织中66种可识别代谢物的水平,以确定组织采集变量的影响。通过分析死后延迟(PMD)0至72小时后采集的大鼠脑皮质和小脑,进一步研究了PMD的影响。在年龄和性别匹配、PMD以及对照Braak分期各不相同的队列中,病例组和对照组之间的代谢物水平无法重复。对大鼠组织的分析发现,在长达72小时的时间段内,PMD对63种已识别代谢物中的31种有显著影响。为了获得可重复的结果,对脑组织进行代谢组学分析时,PMD必须控制在24小时以内。组织在年龄和性别上也应良好匹配,并且对照组的Braak分期应保持在最低水平,以尽量减少这些变量对代谢物变异性的影响。